Galectin Therapeutics

• United States

Sources: sec.gov

• Founded

  Jan 1, 2000

Sources: ror.org

• A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer

  Phase 2, Withdrawn, 0 people, Oct 17, 2006

• Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer

  Phase 2, Withdrawn, 0 people, Oct 11, 2006

• GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer

  Phase 2, Terminated, 20 people, May 13, 2005

• Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors

  Phase 1, Completed, 40 people, Feb 17, 2003

Sources: clinicaltrials.gov

• Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial

  Fees or honoraria, Grants or research support, Feb 5, 2026

• Relationship Between Metabolic and Histological Responses in People With Metabolic Dysfunction- Associated Steatohepatitis With and Without Type 2 Diabetes: Participant-Level Exploratory Analysis of the SYNERGY-NASH Trial With Tirzepatide

  Grants or research support, Dec 1, 2025

• Consistent improvements in liver histology across subgroups in a post hoc analysis of the SYNERGY-NASH trial with tirzepatide

  Grants or research support, Jun 6, 2025

• Review Article: GLP-1 Receptor Agonists and Glucagon/GIP/GLP-1 Receptor Dual or Triple Agonists-Mechanism of Action and Emerging Therapeutic Landscape in MASLD

  Grants or research support, May 13, 2025

• Sex differences in the prevalence and cardiometabolic risk profiles of steatotic liver disease: A Canadian Longitudinal Study on Aging analysis

  Fees or honoraria, Grants or research support, May 5, 2025

Sources: pubmed.ncbi.nlm.nih.gov